DEPDC1 and urinary bladder cancer: Interestingly, the authors generated a cell-permeable peptide inhibitor that corresponded to the DEPDC1 domain required for the interaction with ZNF224, and they were able to inhibit DEPDC1–ZNF224 complex formation, thus resulting in A20 transcription, consequent inactivation of the NF-κB pathway, apoptosis induction and growth suppression of the bladder cancer cells in vivo and in vitro [29].